TScan Therapeutics, Inc.
TCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $188 | $179 | $367 |
| - Cash | $170 | $169 | $154 | $179 |
| + Debt | $89 | $64 | $97 | $97 |
| Enterprise Value | – | $83 | $122 | $286 |
| Revenue | $3 | $3 | $2 | $1 |
| % Growth | -18.4% | 41.7% | 226.5% | – |
| Gross Profit | $2 | $3 | $2 | $1 |
| % Margin | 69.5% | 100% | 100% | 100% |
| EBITDA | -$34 | -$36 | -$33 | -$34 |
| % Margin | -1,363.8% | -1,156.2% | -1,509.4% | -5,160% |
| Net Income | -$36 | -$37 | -$34 | -$36 |
| % Margin | -1,422.1% | -1,201.3% | -1,571.9% | -5,384.8% |
| EPS Diluted | -0.28 | -0.28 | -0.26 | -0.3 |
| % Growth | 0% | -7.7% | 13.3% | – |
| Operating Cash Flow | -$32 | -$33 | -$38 | -$27 |
| Capital Expenditures | -$1 | -$1 | -$2 | -$1 |
| Free Cash Flow | -$34 | -$35 | -$39 | -$28 |